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Abstract
Cardiovascular diseases (CVD) including coronary heart disease and stroke are 
leading causes of death and disability globally. Studies of the association between ABO 
blood groups and CVD have consistently demonstrated an increased risk of coronary 
heart disease, myocardial infarction, cerebral ischaemic stroke, peripheral arterial 
disease and venous thromboembolism (VTE) including deep vein thrombosis and 
pulmonary thromboembolism in patients who possess a non-O blood group type. The 
most likely mechanism is thought to be the increase in von Willebrand Factor (vWF) 
and factor VIII levels seen in patients with a non-O blood group. Other postulated 
mechanisms include elevations in circulating inflammatory markers such as endothe-
lial cell and platelet adhesion molecules in subjects with a non-O blood group. More 
recently, it has also been recognised that individuals with a non-O blood group type 
carry a higher risk of SARS-C0V-2 infection and COVID-19 related complications. The 
increased levels in vWF and factor VIII amongst individuals with a non-O blood group 
who have contracted SARS-CoV-2 infection may result in an additive thrombophilic 
effect to that caused by the SARS-CoV-2 virus. Another postulated mechanism is that 
individuals with an O-blood group are protected by anti-A and B antibodies which 
possibly inhibit the binding of the SARS-CoV-2 spike protein to lung epithelium angio-
tensin converting enzyme-2 receptors. There are over 35 minor blood groups on red 
blood cells, some of which such as Kidd, Lewis and Duffy have been associated with 
CVD either alone or in combination with a non-O blood group allele(s). However, 
their role in SARS-CoV-2 infection and mechanism of action for an association with 
CVD remain unknown. This review explores the relationship between ABO and minor 
blood groups with CVD and VTE, with a focus on potential mechanisms underlying 
this relationship and the potential role of ABO blood group types in COVID.
Keywords: cardiovascular diseases, venous thromboembolism, ABO blood group, 
von Willebrand Factor, COVID
1. Introduction
Cardiovascular diseases (CVD) including coronary heart disease and stroke 
are the global leading cause of death and a major contributor to disability [1]. 
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Traditional modifiable risk factors include hypertension, dyslipidaemia, diabetes 
mellitus, current smoking, obesity and physical inactivity and non-modifiable risk 
factors include age, gender, family history and ethnic background [2]. Amongst 
the non-modifiable risk factors, genetic variations in conjunction with traditional 
modifiable risk factors may significantly influence the trajectory of an individual’s 
CVD risk [3]. Studies on the association between ABO blood group and CVD have 
consistently demonstrated that possession of the O blood group, the most common 
phenotype in most populations [4], confers protection against an individual devel-
oping a cardiovascular event [5–11]. The A and B blood groups are most frequently 
seen in Caucasian and Asian populations, respectively [4]. However, the magnitude 
of the association between CVD and ABO blood grouping across different ethnic 
populations is controversial in part due to the higher population attributable risk of 
traditional modifiable vascular risk factors [9, 10, 12].
There is also a well-documented interaction between ABO blood group and 
venous thromboembolism (VTE) [7, 13–15]. The A2 blood subgroup, which is less 
common than A1 and rare in Asian populations [5], has been reported to be associ-
ated with a modest VTE risk (Odds Ratio 1.2) whereas the A1 and B subgroups confer 
a 1.8-fold increased risk [7]. The non-O blood groups are associated with ~25–30% 
higher plasma levels of factor VIII and von Willebrand Factor (vWF) which are felt 
to be the major contributing factors to the increased risk of VTE [7, 16]. ABO blood 
grouping has been reported to influence activated protein C resistance [8], plasma 
lipid levels [11] and markers of inflammation including soluble intercellular adhesion 
molecule 1 (ICAM1), plasma soluble E-selection and P-selectin and tumour necrosis 
factor-alpha [11]. An additive effect on VTE risk and ABO blood group has also 
been described in association with factor V Leiden and prothrombin gene mutations 
[10, 17]. Finally, ABO blood grouping has more recently been reported to influence 
Figure 1. 
ABO gene and their potential role in COVID-19, cerebral ischaemic disease, peripheral arterial disease, and 
myocardial infarction.
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susceptibility to SARS-CoV-2 infection and an individual’s propensity to more severe 
disease [18–20]. Proposed mechanisms include an additive risk of COVID-19 related 
thrombophilic complications in patients with a non-O blood group and a protective 
role of the O-blood group against the binding of the SARS-CoV-2 spike protein to 
lung epithelium angiotensin converting enzyme-2 receptor [18–20].
There are at least 35 minor blood group antigens in addition to ABO including Kidd, 
MNS, Duffy and Lewis [21] for which some, including Kidd and Lewis, have also been 
associated with CVD although the mechanisms of the associations are unclear [22–24].
This review will focus on the relationship between ABO blood types and CVD 
including coronary artery disease, ischaemic stroke, peripheral arterial disease and 
VTE (Figure 1). The contemporary relationship between SARS-CoV-2 infection, 
CVD and ABO blood grouping and the role of minor blood group antigens in the 
pathogenesis of CVD will also be discussed.
2. The ABO blood group system
The discovery of the ABO blood group system in 1900 by Austrian physician Karl 
Landsteiner saw him awarded of a Nobel Prize in physiology and medicine thirty 
years later [25]. The ABO blood group system consists of three main alleles A, B and 
O with codominant A and B alleles resulting in an inheritance pattern consisting of 
six genotypes and four major blood types [4, 25]. The ABO locus is found on chro-
mosome 9 (9q34.1-q34.2) and codes for 2 glycosyltransferases A and B that transfer 
N-acetyl-D-galactosamine and D-galactose to a H antigen acceptor site on red blood 
cells (RBC) producing A and B surface antigens and blood group types, respectively 
(Figure 2) [26]. Lack of glycosyltransferase activity results in an unmodified ABO 
H antigen precursor and an O blood group type (O standing for ‘Ohne’, the German 
word for ‘without’) [25, 26]. Although ABO blood group antigens are RBC antigens, 
they are also expressed on human tissue including epithelial and endothelial cells [4].
The four basic ABO blood groups are O, A, B and AB. The ABO blood phenotypes 
have multiple subtypes, including A1, A2 and A3, in which 80% of blood group A 
cases are A1 in subtype, and O1, O2 and O3, in which O1 accounts for 95% of blood 
group O cases (Table 1) [4, 26]. From an evolutionary perspective, the oldest blood 
groups are A and O with A1 subtype considered the ancestral blood group [4, 7]. 
Single nucleotide polymorphisms (SNPs) of the ABO gene define the major haplo-
types of European ancestry populations [7]. A substitution from proline to leucine 
at amino acid 156 results in a change from A1 to the less common A2 allele [5, 7]. 
Substitutions from glycine to serine at amino acid 235, leucine to methionine at amino 
acid 266 and glycine to alanine at amino acid 268 results in B allele subtypes [7, 27]. In 
contrast, the O1 type is a consequence of a frameshift deletion of guanine (cdel261G, 
p88fs118Stop) which translates to a protein without enzymatic activity [4, 5, 7].
There are significant geographic and racial variations in the distribution of 
blood groups across the world [4, 25]. Contributing factors include migration over 
the time of humankind’s existence and processes of natural selection influenced 
by environmental factors such as climate and major diseases including malaria 
for which the O blood group confers protection [25]. Blood group A is predomi-
nant in Northern and Central Europe, B in Central Asia and O in Africa, South 
America, and Australia [4, 5, 25]. However, there are isolated populations within 
each continent that have a completely different blood group [4]. For example, the 
O blood group is common in different areas of Europe including Scandinavia and 
Switzerland [10, 25]. The most recent blood group, AB, appears to have arisen 
when A blood group populations in Europe migrated and mixed with B blood group 
populations of Asia [4].
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Due to the association between clotting and ABO blood group, these geographic 
and racial differences may contribute to ethnic differences seen in rates of CVD.
3. ABO blood groups and arterial diseases
There have been numerous retrospective and prospective studies and meta-anal-
yses demonstrating an association between non-O blood groups and CVD events 
[5, 8–12, 24]. These studies have consistently demonstrated an association between 
non-O blood groups and an increased risk of arterial disease including myocardial 
infarction, coronary heart disease, peripheral arterial disease, and ischaemic stroke 
(Table 2). Possible mechanisms for an association with CVD include vWF-related 
thrombosis and modulation of platelet function through other platelet proteins 
which also express ABO antigens such as glycoprotein IIb [5]. The following two 
sections discuss the relationship between ABO blood groups and arterial diseases.
Figure 2. 
Transfer of N-acetyl-D-galactosamine and D-galactose to a H antigen acceptor site on red blood cells (RBC) 
produces A and B surface antigens and blood group types, respectively. Lack of such a transfer result in an 
unmodified ABO H antigen precursor and the O blood group type.
ABO blood groups [25]
A A1, A2, A3 and other rare types including A4, A5, A6, Z, X, End, Boutu, g and i
B B1, B2, B3 and rare types w, x, v and m
Other subtypes O1, O2, O3 and other types including Yy, Hh, Xx and Bombay
Table 1. 
The main ABO groups and their subtypes.
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10,000 males >40 y Israel ↑ MI and angina 
pectoris in A1, B, 
A1Jka−, BJka−
Wu et al. 
2007 [8]
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versus O with 
hazard ratio greater 
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Vasan et al. 
2016 [10]
SCANDAT2 



























arrhythmia & PAD 
in non-O group
Chen et al. 
2016 [9]







↑ coronary heart 
disease in blood 
group A (OR 1.14) 
vs. O (OR 0.89)









China ↑ post-MI 
spontaneous 
recanalization in O 
group










China ↑ HR following MI 
in blood group A
ACS = acute coronary syndrome; C = control subjects; CVD = cardiovascular disease; HR = heart rupture; 
MI = myocardial infarction; OR = Odds Ratio; PAD = peripheral arterial disease; SCANDAT = Scandinavian 
Donations and Transfusions; y = years.
Table 2. 
Subject characteristics and non-O versus O blood group findings for the studies presented in the ABO blood 
groups and arterial diseases section (by year of publication).
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4. ABO and coronary artery disease
In 1971, Medalie et al. reported the findings of a five-year prospective study of 
10,000 Israeli male government employees aged ≥40 years who were born in six 
different regions (Eastern, Central and South-eastern Europe, Israel, Asia, and 
North Africa) [24]. The study found that subjects with blood groups A1, B, and A1B 
tended to have higher rates of myocardial infarction and those with A1 and B had 
higher rates of angina pectoris when compared to other blood groups [24]. Further, 
subjects who were negative for the Kidd glycoprotein (JKa−), a red blood cell urea 
transporter, had the highest rates of myocardial infarction and angina pectoris and 
adding this group to the ABO system (A1Jka−, BJka− and, particularly, A1BJka−) was 
associated with very high incidence rates [24].
A pooled analysis of two large prospective United States (US) cohort studies, 
the Nurses’ Health Study (NHS) which included 62,073 women and the Health 
Professionals Follow-up Study (HPFS) which included 27,428 men, both of which 
had >20 years follow-up, also found that the ABO blood group was significantly 
associated with an increased risk of coronary heart disease for men and women 
[11]. A limitation of these two patient cohorts was the self-reporting of ABO and 
Rh factor status. However, a validation analysis of a subsample of 98 subjects found 
a 93% serologically confirmed ABO consistency for NHS and 90% consistency for 
HPFS. The combined analysis found that those with blood group A, B or AB were 
more likely to develop coronary heart disease and this risk was independent of 
age, level of physical activity, alcohol or smoking consumption or diabetes history 
[5, 11]. A meta-analysis, performed by the same authors, of 7 cohort studies includ-
ing NHS and HPFS which combined a total of 114,648 individuals and 5,741 coro-
nary heart disease cases found a significant pooled relative risk for coronary heart 
disease in patients with a non-O blood group of 1.1 (95% CI 1.05–1.18, p = 0.0001). 
Subjects with an O blood group had a lower risk for coronary heart disease when 
compared to B or AB with a trend seen for blood group A [5, 11].
ABO blood group status may be clinically relevant in subjects with concur-
rent cardiovascular risk factors. A study of 289 Italian blood donors with a high 
cardiovascular risk score (≥20) found that those with a non-O blood group had an 
increased risk of CVD events (including acute coronary syndrome, cerebral isch-
aemia, cardiac arrhythmias and supraaortic trunk or iliac artery stenosis) during 
a median follow-up of 5.3 years [6]. ABO blood group status may also influence 
CVD-related patient outcomes. In a study of 1209 patients with acute myocardial 
infarction, Lin et al. found a higher rate of spontaneous recanalization following 
myocardial infarction in association with the O blood group whereas the rate of 
spontaneous recanalization was lower in subjects with an A blood group [28]. Blood 
group A type has also been associated with an increased risk of heart rupture fol-
lowing myocardial infarction [29]. Hence, ABO blood type may not only predispose 
susceptible individuals to an increased risk of CVD events but may also influence 
post-myocardial infarction outcomes.
5. ABO, stroke, and arterial disease in general
ABO blood group status has been shown to influence stroke risk. An associa-
tion of AB blood group with stroke (adjusted Hazards Ratio [aHR] 1.83, 95% CI 
1.01–3.30) was found in the (Reasons for Geographic And Racial Differences in 
Stroke [REGARDS]) study which involved 30,239 US participants followed up over 
5.8 years [12]. This finding remained significant after adjustment for age, gender, 
race region and Framingham stroke risk factors (systolic blood pressure, taking 
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antihypertensive medication, diabetes, current smoking, atrial fibrillation and left 
ventricular hypertrophy). The association was greater in those participants without 
diabetes mellitus (aHR 3.33 95% CI, 1.61–6.88). Factor VIII levels accounted for 
60% of the AB associated stroke risk [12]. Another study by Wiggins et al. identi-
fied an increased risk of ischaemic stroke in subjects with a B blood group (OR 1.59, 
95% CI 1.17–2.17) [30].
Meta-analysis studies have also demonstrated associations between non-O blood 
groups and arterial diseases in general. Chen et al. performed a meta-analysis of 17 
studies involving 225,810 participants and found that blood group A was associ-
ated with an increased risk of coronary artery disease (OR 1.14, 95% CI 1.03–1.26, 
p = 0.01) and blood group O a lower risk (OR 0.85, 95% CI 0.78–0.94, p < 0.001) 
[9]. These results remained significant after cases of myocardial infarction were 
excluded. Wu et al. conducted a systematic review and meta-analysis of 59 studies, 
both retrospective and prospective, reporting associations of ABO blood groups 
and arterial disease [8]. They found significant ORs of 1.25 (95% CI 1.14–1.36) 
for myocardial infarction (n = 22 studies), 1.45 (95% CI 1.35–1.46) for peripheral 
arterial disease (n = 8 studies) and 1.14 (95% CI 1.01–1.27) for cerebral ischaemia of 
arterial origin (n = 7 studies) in subjects with a non-O blood group [8].
6. ABO blood groups and venous thromboembolism
The relationship between the ABO blood groups and VTE is most probably 
stronger than that seen in arterial diseases [5]. The association between blood 
group subtypes and VTE has been well documented in a few genome-wide associa-
tion (GWAS) [5, 31, 32], meta-analyses and/or case–control studies [7, 8, 10, 13] 
(Table 3). A French GWAS study involving 419 patients with early age onset of 
first deep vein thrombosis (DVT) who were compared to 1228 controls found that 
participants with blood type O had a 67% lower risk of VTE compared to n those 
with a non-O blood group [5, 31]. Relative to other non-O groups, subjects with 
the uncommon A2 subtype had a 47% lower risk [5, 31]. In the same study, Factor 
V Leiden mutations were also associated with increased risk of VTE although the 
authors did not investigate the potential for an additive risk in those having both a 
non-O blood group and a Factor V Leiden mutation [31]. A similar association of 
non-O blood group with VTE was found in another GWAS study comparing 1503 
VTE subjects to 1459 age and gender matched controls [32]. In this study, the popu-
lation attributable risk for VTE was highest for the non-O blood group, followed by 
blood type A, Factor V Leiden, and prothrombin G20210A [32].
There is evidence that the A2 subtype of blood group A is associated with a 
lower VTE risk when compared to the A1 allele [5, 33]. The A2 allele possesses a 
single base deletion near its carboxyl terminal (1061delC) which results in 30 to 
50-fold less A-transferase activity than its A1 counterpart which suggests a correla-
tion between the degree of H antigen glycosylation and VTE risk [33]. Data from 2 
population-based case control studies that included 504 post-menopausal women 
with non-fatal VTE found that the B and AB blood groups were both associated 
with an increased risk of VTE (OR 1.82, 95% CI 1.29–2.57, and OR 2.7, 95% CI 
1.73–4.21, respectively) when compared to O1O1 subjects [30]. Participants with 
A11, a subtype of the A1 allele, also carried a 79% increased risk of VTE (OR 1.79, 
95% CI 1.41–2.26) [30]. An increased VTE risk was also identified in a population-
based case control study of venous thrombosis (Leiden Thrombophilia Study) [34]. 
In this study, an increased thrombotic risk was found for non-O blood groups apart 
from those with genotypes homozygous to A2 or possession of any A2/O combina-
tion. Subjects with A1B/A2B and A1A1/A1A2 blood group genotypes had a 90–110% 
Blood Groups - More Than Inheritance of Antigenic Substances
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increased risk and those with BB/BO1/B02 genotypes had a 60% increased risk 
when compared to the OO genotype [34].
In a pooled analysis of 6 case–control/prospective studies of VTE, the A2 
subgroup was found to be associated with a modest increase in VTE risk (OR 1.2) 
whereas the A1 and B subgroups had a 1.8-fold increased risk compared to the O1 
subgroup. In contrast, O2 had a relative protective effect (OR 0.8) [7]. Both the A1 
Study and 
year
Type of study Subjects Age range Country Findings (non-O 
versus O)











↑ VTE for all non-O 
blood group except 
A2A2 or any A2O 
combination
Wu et al. 
2007 [8]




Multiple Multiple ↑ VTE in A1A2/A1B/BB 
(OR 2.44) & A!O/BO/
A2B (OR 2.11) blood 
groups











Brazil ↑ VTE for FVL (OR 
10.1) and double ↑ risk 
if also AB (OR 22.3)
Trégouët 











France ↑ VTE in non-O blood 
group, relative lower 
risk VTE of A2 amongst 
non-O subjects and 
additive risk of FVL 
mutation
Wiggins 














↑ VTE in B (OR 1.82), 
AB (OR 2.7) & A11 (OR 
1.79) compared to O1O1 
blood group














↑ VTE population 
attributable risk 
for non-O blood 
group followed by A 
blood group, FVL & 
prothrombin G20210A
Vasan et al. 
2016 [10]
SCANDAT2 











↑ VTE including 
pregnancy-related VTE 
& DVT in non-O blood 
group





1412 VTE & 
199,248 C
Mean 57.3 
y VTE & 
47.5 C












↑ VTE for A2 (OR 1.2), 
A1 & B (OR 1.8) & ↓ 
VTE for O2 (OR 0.8) 
compared to O1
C = control subjects; DVT = deep vein thrombosis; FVL = Factor V Leiden; GWAS = genome-wide association study; 
LETS = Leiden Thrombophilia Study; MP = menopausal; OR = Odds Ratio; PTE = pulmonary thromboembolism; 
SCANDAT = Scandinavian Donations and Transfusions; VTE = venous thromboembolism; y = years.
Table 3. 
A summary of subject characteristics and non-O versus O blood group findings for the studies presented in the 
ABO blood groups and VTE section (by year of publication).
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and B subgroups were associated with increased vWF and factor VIII plasma levels 
whereas only the A1 subgroup was associated with increased ICAM levels [7]. A 
meta-analysis of 21 VTE studies, 18 of which were retrospective in design, found 
a pooled OR of 1.79 (95% CI 1.56–2.05) for non-O blood group and VTE [7]. The 
combination of A1A1/A1B/BB genotypes had an OR of 2.44 (95% CI 1.79–3.33) and 
A1O/BO/A2B an OR of 2.11 (95% CI 1.66–2.68) for VTE [8].
The presence of a non-O blood group has been found to correlate with unpro-
voked PTE, provoked including pregnancy induced and recurrent VTE. In a 
Scandinavian 25-year follow-up study of >1.6 million blood donors, those with a 
non-O blood group had higher rates of pregnancy-related VTE events, DVT and 
pulmonary embolism [10]. The risks of recurrent pulmonary embolism and DVT 
provoked by comorbid illness were also higher in subjects with a non-O blood group 
[10]. A large hospital-based retrospective study of 200,660 Han Chinese patients 
including 1412 VTE subjects (600 with DVT, 441 with pulmonary embolism and 
371 with both conditions) conducted between 2010 and 2016 found a significant 
association of non-O blood group with VTE (OR 1.35, 95% CI 1.21–1.54) [13]. 
Interestingly, subgroup analysis found a relatively greater non-O blood group risk 
for those with an unprovoked VTE (OR 1.86) compared to provoked VTE (OR 
1.22). The OR for having a non-O blood group also appeared to decrease with age 
[13]. Finally, a Brazilian case control study comparing 65 subjects with a history of 
DVT to 51 controls showed a significant increased risk of VTE in the presence of 
Factor V Leiden mutation (OR 10.1) which doubled in those in whom the AB allele 
of the ABO blood group was also present (OR 22.3) [17].
Future research into the role of developing risk stratification models or algo-
rithms, for example, by combining ABO and other genetic variables with patient 
comorbidity and arterial risk factors to identify individuals at higher risk of VTE 
is warranted. This may translate to improved cardiovascular disease management 
including decision making for VTE prophylaxis at the hospital and outpatient 
setting.
7.  Von Willebrand factor, factor VIII and other factors associated with 
ABO blood group and CVD
The majority of studies that have been presented in this review implicate an 
increase in plasma levels of vWF and factor VIII by non-O blood group types as the 
likely mechanism for an increased risk of thromboembolic events [5–13]. VWF/
factor VIII are important in the acute phase response to vessel injury [8]. VWF is 
a carrier of factor VIII, protects it from inactivation, can also recruit platelets to a 
site of vessel injury to induce a coagulation cascade responsible for clot formation 
[5]. VWF can also bind to the platelet receptor glycoprotein Iba, to form a bridge 
between platelets and the endothelium and participate in a thrombo-inflammatory 
response (Figure 3) [35, 36].
ABO blood groups may have a direct functional effect on circulating vWF and 
thereby modulate both vWF and factor VIII levels [5]. The mechanism by which 
the presence of an N-acetyl-D-galactosamine or D-galactose residue on glycans 
expressed on the H antigen acceptor site of a RBC influences plasma levels and/
or bioactivity of vWF is unclear [16]. A plausible mechanism is that ABO glycans 
on vWF itself influence its release into plasma and/or its clearance [16]. VWF is 
derived from a pre-pro-polypeptide (ppvWF) synthesized in endothelial cells and 
megakaryocytes [16]. The expression of blood antigen A on vWF correlates with 
decreased ppvWF to vWF ratios as well as longer half-life and increased plasma 
levels of vWF [16].
Blood Groups - More Than Inheritance of Antigenic Substances
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It has been postulated that the presence of A and B terminal carbohydrate 
antigens influence the proteolysis of vWF by its major protease ADAMTTS13 (a 
disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 
- also known as von Willebrand factor-cleaving protease [VWFCP]) [5]. Individuals 
lacking glycosyltransferase activity (O blood group) have higher levels of 
ADAMTS13 activity suggesting that ABO glycosyltransferase activity can indirectly 
modify, for example, inhibit proteolytic activity and reduce vWF clearance from 
the circulation [5]. However, there are studies which have not supported this as the 
underlying mechanism [37]. Future research into other, yet to be determined, ABO 
blood group and VWF-related associations may unravel the underlying mechanism 
of a non-O blood group increased risk of thrombosis.
Blood group antigens are also associated with elevated plasma levels of markers 
of inflammation including endothelial cell and platelet-derived adhesion molecules 
[5]. Elevated plasma levels of adhesion molecules including soluble P-selectin, sol-
uble ICAM-1 and tumour necrosis factor-alpha are associated with ABO genotype, 
which may result in arterial and venous thrombosis and an increased CVD risk  
[5, 11]. However, in studies reporting the circulating expression levels of sICAM-1 
and soluble P-selectin, the blood group A has paradoxically been found to be associ-
ated with lower circulating expression levels of sICAM-1 and soluble P-selectin 
when compared to the O blood group [38, 39]. This contradictory finding has been 
described in healthy Chinese populations and a study of Caucasian women without 
a history of chronic disease [38, 39]. A postulated explanation for why blood group 
A, in general, may be associated with lower circulating inflammatory markers 
despite carrying a higher CVD risk is that higher levels of sICAM-1 or soluble 
P-selectin expression are limited to those with significant CVD risk factors and/
or symptomatic CVD. The concentrations of membrane forms of these adhesion 
Figure 3. 
Von Willebrand factor (vWF) can bind to the platelet receptor glycoprotein Ib (GPIb) to form a bridge 
between platelets and the endothelium and a thrombo-inflammatory response. The protease ADAMTTS13 
(a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is responsible for the 
proteolysis and clearance of vWF from the circulation.
11
Are ABO Gene Alleles Responsible for Cardiovascular Diseases and Venous Thromboembolism…
DOI: http://dx.doi.org/10.5772/intechopen.100479
molecules may also higher and thereby still mediate leucocyte migration and adhe-
sion at an endothelial level [39]. It is also possible that reduced levels of sICAM-1 
increase the adhesion of leukocytes on endothelial surfaces which may result in 
increased arterial inflammation [40].
Platelet glycoproteins including GPIIb, and platelet endothelial cell adhesion 
molecule are known to carry ABO blood group antigens and may be involved in 
thrombosis through modulation of the GPIIb-GPIIIa fibrinogen receptor complex 
[5]. A relationship between ABO blood group and angiotensin converting enzyme 
activity has also been reported which implicates a role for ABO blood group in the 
regulation of arterial risk factors such as hypertension [41].
Epidemiological studies have demonstrated an association between an elevated 
serum cholesterol including low-density lipoprotein cholesterol and non-O blood 
groups [5, 42]. These findings implicate ABO genotypes in the modulation of 
plasma lipids. ABO blood groups are also associated with phytosterol levels which 
have also been reported to modify cardiovascular risk [5].
8. ABO blood group, COVID-19, and CVD
There is growing evidence that ABO blood groups may play a role in the suscep-
tibility to and severity of SARS-CoV-2 infection [18–20]. Individuals with blood 
group O have a lower risk and those with blood group A carry a higher risk of SARS-
CoV-2 infection [18]. A systematic review by the International Society of Blood 
Transfusion (ISBT) COVID-19 working group recently reported that subjects with 
blood group A had a higher rate of SARS-CoV-2 infection as well as an increased 
risk of requiring mechanical ventilation, continuous renal replacement therapy 
and prolonged intensive care unit stay [18]. Postulated mechanisms include an 
increase in angiotensin converting enzyme-1 levels in blood group A patients and an 
increased risk of cardiovascular, thromboembolic, and inflammatory complications 
[18]. It is plausible that possession of a non-O blood group and associated increase 
in vWF and factor VIII levels have an additive effect to the thrombophilia caused 
by SARS-CoV-2 and results in an increased risk of COVID-related CVD complica-
tions [18–20]. A recent hypothesis for an association between non-O blood group 
type and risk of SARS-CoV-2 infection is that anti-A and/or anti-B antibodies, 
which are present in patients with blood group O bind to a corresponding antigen, 
for example the angiotensin-converting-enzyme-2-receptor, on the SARS-CoV-2 
viral envelope which then inhibits viral entry into lung epithelium (Figure 4) [18]. 
Although ABH antigen structures are yet to be described on the SARS-CoV-2 pro-
tein, the spike protein has been reported to possess N-glycans and N-glycosylation 
sites which could potentially interact with anti-A and anti-B antigens and thus 
confer protection against infection in individuals with the blood group O type [18]. 
The possibility that blood group A patients also have higher rates of underlying 
comorbidities which significantly contribute to COVID-related complications can-
not be excluded [18].
A single-centre study from Bangladesh which evaluated 438 patients with SARS-
CoV-2 infection also found a significantly higher rate of blood group A amongst 
COVID-19 patients compared to the general population [20]. However, ABO blood 
groups were not associated with type of presentation or recovery from infection 
[20]. Conversely, an observational study of 14,112 individuals tested for SARS-CoV-2 
in the New York Presbyterian hospital system found that risk of intubation was 
increased for AB and B blood groups but decreased for A when compared to O blood 
group and risk of death was increased for those with AB blood group and decreased 
for A and B blood groups [19]. Interestingly, Rhesus status, which is not implicated 
Blood Groups - More Than Inheritance of Antigenic Substances
12
in CVD risk, correlated with COVID-19 risk [19]. Rhesus-negative subjects had a 
lower risk of SARS-CoV-2 infection, intubation, and death [19]. The mechanism of 
the relationships of ABO blood group, Rhesus status and SARS-CoV-2 infection is 
unknown. Further research into the relationship between blood groups and risk of 
SARS-CoV-2 infection and COVID-19 related complications is warranted.
9. Minor blood group antigens and CVD
There are over 35 minor blood group antigens on red blood cells [21], some of 
which including P and Lewis, are widely distributed in other human cells and body 
fluids [43, 44]. Minor blood groups have been associated with several diseases 
ranging from malignancy to peptic ulcer disease, infection and CVD [43, 44]. As 
discussed previously, subjects with a combination of blood groups A or B and the 
Kidd antigen Jka− status have been shown to be at increased risk of myocardial 
infarction [24]. Sialyl-Lex (sLex), an antigen of the Lewis blood group system, is 
a major ligand for the cellular adhesion molecules E, P and L-selectin which are 
involved in the adhesion of leucocytes to endothelium [44]. The Duffy blood group 
glycoprotein is a chemokine receptor on RBCs that is involved in the recruitment 
Figure 4. 
A hypothesis for an association between non-O blood group type and risk of SARS-CoV-2 infection is that 
anti-A and/or anti-B antibodies may bind to the angiotensin-converting-enzyme-2-receptor on the SARS-CoV-2 
viral envelope and thereby inhibit viral entry into lung epithelium. Top left shows blood group O with anti-A 
and anti-B antibodies in the plasma. Top right illustrates anti-A antibodies of blood group O which potentially 
competitively bind to the spike protein of SARS-CoV-2 and thus inhibit infection. Lower left shows blood group 
A with A-antigens on the membranes of red blood cells. Lower right depicts ABH glycans on the SARS-CoV-2 
spike protein which potentially competitively bind to angiotensin converting enzyme 2 (ACE2) receptors.
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of leucocytes to sites of inflammation [44]. Although the exact mechanisms are 
unclear, these biological characteristics offer explanation why the Lewis and Duffy 
blood group antigens may be associated with an increased risk of CVD.
The Lewis blood group system, which was first discovered by Mourant in 1946, 
is classified into four phenotypes [Le(a-b-), Le(a + b-), Le(a-b+), Le(a + b+)] 
determined by two genetic systems closely related on the short arm of chromosome 
19 [45]. In a study of 3385 Danish males, the Le(a-b-) phenotype was associated 
with an increased risk of mortality from ischaemic heart disease [46]. In another 
Danish study involving 702 participants (72% male), the Le(a-b-) was associated 
with self-reported non-fatal stroke [47]. However, a North Indian cross-sectional 
study that compared 161 patients with angiographically-proven coronary artery 
disease with 71 control subjects with normal angiography, found that the lack of 
Lewis antigen expression was associated with coronary artery disease in female 
subjects only [48]. A lack of Lewis antigen expression has also been associated with 
a higher body mass index, weight gain over time, a lower level of physical activity, 
type 2 diabetes mellitus and hypertriglyceridemia all of which associated with an 
increased risk of CVD [49–52].
The Duffy antigen, located on the long arm of chromosome 1 [53], has also 
been implicated in CVD risk [54]. There are four Duffy phenotypes [Fy(a-b-), 
Fy(a + b-), Fy(a-b+), Fy(a + b+) [53]. A study of 5301 African American partici-
pants found that Duffy negative subjects with a neutrophil: lymphocyte ratio ≥ 1.77 
were more likely to have coronary artery disease and stroke [54]. Lack of Duffy 
expression has also been associated with chronic organ damage, in particular renal 
dysfunction, in subjects with sickle-cell disease [55].
To the best of our knowledge, there have been no studies to date addressing the 
relationship of minor blood groups and COVID-19.
The limitations of studies evaluating the role of minor blood groups in CVD 
include their observational cohort design, case selection, outcome definitions, 
cohort sizes and influence of population attributable factors.
10. Conclusion
Subjects with non-O blood group type have an increased risk of arterial and 
venous thromboembolism. Blood groups A1, B and AB are at particularly increased 
risk of CVD events whereas blood group O confers a protective effect. Postulated 
mechanisms of underlying the relationship between ABO blood group and CVD 
include vWF and factor VIII activity and elevations in circulating inflamma-
tory markers and plasma lipids. Comorbidities including arterial risk factors and 
predisposing factors to VTE such as concomitant Factor V Leiden mutations may 
have an additive effect to thromboembolic risk. Minor blood group types includ-
ing Kidd, Lewis and Duffy are also been associated with CVD. The relationship 
of non-O blood group type and SARS-CoV-2 infection warrants further research. 
Future directions include the development and implementation of risk stratification 
algorithms for thromboembolic risk such as ABO blood group and other factors 
associated with arterial or venous disease in a hospital or outpatient setting.
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